NCT06237127

Brief Summary

The goal of this project is to conduct a clinical trial in 60 participants ranging from age 65-95 who are at risk for age-related macular degeneration (AMD). The study will evaluate the effects of 14g of goji berry intake or an equivalent amount and type of fiber, five days a week for six months, on visual health, gut microbiome profiles, skin carotenoid measures, and lipoprotein profiles.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for not_applicable

Timeline
14mo left

Started Apr 2024

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress64%
Apr 2024Jun 2027

First Submitted

Initial submission to the registry

January 19, 2024

Completed
13 days until next milestone

First Posted

Study publicly available on registry

February 1, 2024

Completed
3 months until next milestone

Study Start

First participant enrolled

April 29, 2024

Completed
2.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2026

Expected
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2027

Last Updated

June 24, 2025

Status Verified

June 1, 2025

Enrollment Period

2.2 years

First QC Date

January 19, 2024

Last Update Submit

June 17, 2025

Conditions

Keywords

Goji BerryAge-Related Macular DegenerationLuteinZeaxanthinFiberCarotenoidsGut MicrobiomeHDLCholesterol Efflux CapacityEye Health

Outcome Measures

Primary Outcomes (1)

  • Macular pigment optical volume (MPOV)

    MPOV provides an objective measure of macular pigments by using dual wavelength autofluorescence using the Heidelberg Spectralis to obtain HRA + OCT measures

    Day 0 and Day 180

Secondary Outcomes (13)

  • Stool microbiome

    Day 0 and Day 180

  • Spectral Domain-Ocular Coherence Tomography (SD-OCT)

    Day 0 and Day 180

  • Fundus autofluorescence (FAF)

    Day 0 and Day 180

  • Color Fundus Photography (CFP)

    Day 0 and Day 180

  • Microperimetry testing

    Day 0 and Day 180

  • +8 more secondary outcomes

Study Arms (2)

Goji berry

EXPERIMENTAL

For the goji berry arm, participants will consume goji berries.

Dietary Supplement: Goji berry

Fiber

ACTIVE COMPARATOR

For the fiber arm, participants will consume fiber supplements that closely matches the fiber type and amount found in the portion of goji berries.

Dietary Supplement: Fiber

Interventions

Goji berryDIETARY_SUPPLEMENT

Participants will be instructed to consume 14 grams of goji berries 5 days a week for 6 months

Goji berry
FiberDIETARY_SUPPLEMENT

Participants will be instructed to consume the fiber supplements 5 days a week for 6 months

Fiber

Eligibility Criteria

Age65 Years - 95 Years
Sexall
Healthy VolunteersYes
Age GroupsOlder Adult (65+)

You may qualify if:

  • Family history of AMD
  • Hyperlipidemia or managed diabetes
  • years of age

You may not qualify if:

  • Dislike of, or allergy to, goji berries or any of the ingredients in the fiber-rich wafers and gummies (wheat, corn, oats, soy, natural orange flavor, xylitol, annatto, pectin, or other food ingredients)
  • Consumption of \> 2 alcoholic drinks per day
  • Indications of substance or alcohol abuse
  • Current or planned use of a blood thinner (e.g., Coumadin, Warfarin) at any time during study
  • Use of multi-vitamin or any other supplements that contain lutein and/or zeaxanthin (if willing to stop the supplement, subject can be enrolled 6 months from stop date)
  • Any planned international travel during the study
  • Consuming \>3 servings/day of a combination of spinach, kale, lettuce, orange bell peppers, corn, parsley, squash, broccoli, pumpkin, edamame
  • Regularly consuming \>3 eggs/day
  • Currently participating in any other interventional research study
  • Diagnosed with inflammatory bowel disease, irritable bowel syndrome, other gastrointestinal disorder, undergoing cancer therapy or immunocompromised, or diagnosis of another condition where lutein, zeaxanthin and/or fiber supplementation would be contraindicated or would interfere with ability to participate in the study
  • Any physical characteristic or condition that precludes ability to perform study procedures
  • Medical or psychiatric condition that, in the opinion of the Investigator, would compromise study findings or prevent the participant from completing the study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

UC Davis Eye Center, Tschannen Eye Institute

Sacramento, California, 95817, United States

RECRUITING

MeSH Terms

Conditions

Macular Degeneration

Interventions

Dietary Fiber

Condition Hierarchy (Ancestors)

Retinal DegenerationRetinal DiseasesEye Diseases

Intervention Hierarchy (Ancestors)

Dietary CarbohydratesCarbohydratesFoodDiet, Food, and NutritionPhysiological PhenomenaFood and Beverages

Study Officials

  • Robert M Hackman, PhD

    University of California, Davis

    PRINCIPAL INVESTIGATOR
  • Angela M Zivkovic, PhD

    University of California, Davis

    PRINCIPAL INVESTIGATOR
  • Glenn Yiu, MD, PhD

    University of California, Davis

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Denise Macias, CCRP

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Research Nutritionist

Study Record Dates

First Submitted

January 19, 2024

First Posted

February 1, 2024

Study Start

April 29, 2024

Primary Completion (Estimated)

June 30, 2026

Study Completion (Estimated)

June 30, 2027

Last Updated

June 24, 2025

Record last verified: 2025-06

Data Sharing

IPD Sharing
Will not share

Locations